Goldman Sachs’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Goldman Sachs’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Hold	0	–	-$25K	–	7321
2016 Q2	–	Sell	-13	Closed	-$1.53M	–	6651
2016 Q1	$1.75M	Hold	13	–	–	﹤0.01%	3601
2015 Q4	$1.8M	Hold	13	–	–	﹤0.01%	3730
2015 Q3	$2.15M	Buy	+13	New	+$3.04M	﹤0.01%	3710

Goldman Sachs's NVIV Position: Q2 2024 in Review

Goldman Sachs sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2024, closing a stake of 23,741 shares — an estimated $5.22K sold.

Goldman Sachs first reported a position in NVIV in Q2 2015 and held it in 13 quarters. The position peaked at $2.44M in Q1 2016. 0 funds tracked by Wall St. Rank hold NVIV as of Q2 2024.

Goldman Sachs reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2024 after selling out during the quarter.
Goldman Sachs sold 23,741 InVivo Therapeutics Holdings Corp shares in Q2 2024, an estimated $5.22K.
Goldman Sachs first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 13 quarters.
Goldman Sachs's InVivo Therapeutics Holdings Corp position peaked at $2.44M in Q1 2016.
0 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.